An artificial intelligence-designed vaccine intended to protect against multiple coronaviruses passed its first human clinical trial, according to researchers at the Universities of Cambridge and Southampton.
The vaccine was designed to target Sarbeco coronaviruses, a group that includes SARS-CoV-2, which caused the COVID-19 pandemic. In a university news release, researchers said they used available genetic sequence data for Sarbeco coronaviruses to design a “super-antigen” containing features common across the group, including viruses that have not yet emerged.
Traditional vaccines often must be updated as viruses mutate. “Viruses like Influenza, coronaviruses and the Ebola group are evolving continuously, and by the time vaccines are rolled out, they may be poorly matched — the current ‘reactive’ vaccine system struggles to keep pace,” said Saul Faust, a University of Southampton professor and the trial’s chief investigator.
The early-stage trial found the vaccine was safe and triggered an immune response in 39 healthy volunteers. Researchers said it was “the first time that a vaccine whose active component was designed entirely by computer simulations has been tested in humans.”
The vaccine was delivered through the skin with a micro-fluid jet, which uses a small, high-pressure stream of liquid instead of a needle. Researchers said that method could make large-scale administration faster and easier.
Faust said, “This new class of universal vaccines are future-proofed. They not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans. If we can develop and clinically advance this new class of vaccines before a virus outbreak begins, millions of lives could be saved, lockdowns avoided and the economy preserved.”